Brain 17 Vienna
PROFILE trial 1014
ALK+ advanced NSCLC
randomise
crizotinib
cisplat/carbo pemetrexed
172 patients
171 patients
343 patients
Brain metastases in patients with ALK-positive NSCLC
Solomon et al 2016, J Clin Oncol; 34 (24), 2858-65
Made with FlippingBook - Online catalogs